ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
May 09, 2019IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system ... -
Novartis strengthens anti-inflammatory drugs portfolio with IFM Tre buy
April 02, 2019In a deal potentially worth $1.6 billion, Novartis is set to acquire IFM Therapeutics' IFM Tre unit. -
IFM Therapeutics' inflammation-focused subsidiary debuts with $31M
July 26, 2018IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre. The new unit, which starts out with $31 million in series A funding, expects to bring its lead asset into phase 1 in 2019.
Pharma Sources Insight January 2025
